» Articles » PMID: 38813710

Myeloid Neoplasm with Histiocytosis and Spleen Tyrosine Kinase Fusion Responds to Fostamatinib

References
1.
Zeitlmann L, Knorr T, Knoll M, Romeo C, Sirim P, Kolanus W . T cell activation induced by novel gain-of-function mutants of Syk and ZAP-70. J Biol Chem. 1998; 273(25):15445-52. DOI: 10.1074/jbc.273.25.15445. View

2.
Sada K, Zhang J, Siraganian R . Point mutation of a tyrosine in the linker region of Syk results in a gain of function. J Immunol. 1999; 164(1):338-44. DOI: 10.4049/jimmunol.164.1.338. View

3.
Crowley H, Georgantzoglou N, Tse J, Williams E, Mata D, Martin S . Expanding Our Knowledge of Molecular Pathogenesis in Histiocytoses: Solitary Soft Tissue Histiocytomas in Children With a Novel CLTC::SYK Fusion. Am J Surg Pathol. 2023; 47(10):1108-1115. DOI: 10.1097/PAS.0000000000002102. View

4.
Bussel J, Arnold D, Grossbard E, Mayer J, Trelinski J, Homenda W . Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018; 93(7):921-930. PMC: 6055608. DOI: 10.1002/ajh.25125. View

5.
Mahmoodi M, Swami V, Besa E, Punnett H . A second case of myelodysplastic syndrome with t(9;12)(q22;p12). Cancer Genet Cytogenet. 2005; 157(2):187-8. DOI: 10.1016/j.cancergencyto.2004.08.002. View